Valbonne, France

Marie-Cecile Lenoir-Viale


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1998

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Marie-Cecile Lenoir-Viale: Innovator in Therapeutic Compositions

Introduction

Marie-Cecile Lenoir-Viale is a prominent inventor based in Valbonne, France. She has made significant contributions to the field of pharmaceutical and dermatological compositions. Her innovative work focuses on therapeutic compositions that target specific receptors to modulate cell proliferation and differentiation.

Latest Patents

Marie-Cecile Lenoir-Viale holds one patent titled "Synergistic therapeutic compositions comprising at least one ligand." This patent describes pharmaceutical and dermatological compositions that include a first ligand with selective activity for RXR receptors and a second ligand with selective activity for the RAR-.alpha. receptor. These compositions are particularly useful for the systemic treatment of acute promyelocytic leukemia by modulating the proliferation and differentiation of HL-60 type cells.

Career Highlights

Marie-Cecile Lenoir-Viale is associated with the Centre International de Recherches Dermatologiques Galderma. Her work at this institution has allowed her to explore innovative solutions in dermatology and pharmaceuticals. She has dedicated her career to advancing therapeutic options for patients.

Collaborations

Some of her notable coworkers include Serge Michel and Christine Cathelineau. Their collaborative efforts contribute to the ongoing research and development in the field of dermatological therapies.

Conclusion

Marie-Cecile Lenoir-Viale's contributions to therapeutic compositions highlight her role as an innovator in the pharmaceutical industry. Her work continues to impact the treatment of serious medical conditions, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…